Last reviewed · How we verify
MYLAN SPECIALITY LP — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Felbatol | FELBAMATE | marketed | Anti-epileptic Agent [EPC] | NMDA receptor-ionophore complex | Neuroscience | 1993-01-01 |
| Soma | CARISOPRODOL | marketed | Muscle Relaxant [EPC] | Neuroscience | 1959-01-01 |
Therapeutic area mix
- Neuroscience · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Pfizer · 2 shared drug classes
- Bausch Health · 1 shared drug class
- GSK · 1 shared drug class
- · 1 shared drug class
- Hikma · 1 shared drug class
- Johnson & Johnson · 1 shared drug class
- Generic (originally Abbott/AbbVie) · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for MYLAN SPECIALITY LP:
- MYLAN SPECIALITY LP pipeline updates — RSS
- MYLAN SPECIALITY LP pipeline updates — Atom
- MYLAN SPECIALITY LP pipeline updates — JSON
Cite this brief
Drug Landscape (2026). MYLAN SPECIALITY LP — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mylan-speciality-lp. Accessed 2026-06-10.